771 related articles for article (PubMed ID: 7534744)
21. [Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma].
Zhou SY; Shi YK; He XH; Zhang P; Dong M; Huang DZ; Yang JL; Zhang CG; Liu P; Yang S; Feng FY
Ai Zheng; 2005 Apr; 24(4):465-9. PubMed ID: 15820071
[TBL] [Abstract][Full Text] [Related]
22. High-dose chemotherapy with carboplatin, etoposide and ifosfamide followed by autologous stem cell rescue in patients with relapsed or refractory malignant lymphomas: a phase I/II study.
Kleiner S; Kirsch A; Schwaner I; Kingreen D; Schwella N; Huhn D; Siegert W
Bone Marrow Transplant; 1997 Dec; 20(11):953-9. PubMed ID: 9422474
[TBL] [Abstract][Full Text] [Related]
23. How do patients with aggressive non-Hodgkin's lymphoma treated with third-generation regimens (MACOP-B and F-MACHOP) fare in the long-term?
Zinzani PL; Martelli M; Magagnoli M; Zaja F; Storti S; Pavone E; Lauta VM; De Renzo A; Gobbi M; Bocchia M; Ronconi F; Scaramucci L; Gherlinzoni F; Palombi F; Bendandi M; Stefoni V; Anticoli Borza P; Cellini C; Mandelli F; Tura S
Haematologica; 1999 Nov; 84(11):996-1001. PubMed ID: 10553159
[TBL] [Abstract][Full Text] [Related]
24. Etoposide, ifosfamide, and methotrexate combination chemotherapy for aggressive non-Hodgkin's lymphomas after failure of the LNH 84 regimen.
Herbrecht R; Damonte JC; Dufour P; Maloisel F; Liu KL; Ortiz S; Bergerat JP; Oberling F
Semin Oncol; 1992 Feb; 19(1 Suppl 1):7-10. PubMed ID: 1384135
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of two different ProMACE-CytaBOM derived regimens in advanced aggressive non-Hodgkin's lymphoma. Final report of a multicenter trial conducted by GISL.
Federico M; Clò V; Brugiatelli M; Carotenuto M; Gobbi PG; Vallisa D; Lombardo M; Avanzini P; Di Renzo N; Dini D; Baldini L; Silingardi V
Haematologica; 1998 Sep; 83(9):800-11. PubMed ID: 9825577
[TBL] [Abstract][Full Text] [Related]
26. [High-dose chemotherapy and autologous stem cell transplantation for refractory and relapsing Hodgkin's disease as first-line therapy-- studies at Sheba Medical Center--Tel Hashomer].
Avigdor A; Hardan I; Shpilberg O; Raanani P; Grotto I; Ben-Bassat I
Harefuah; 2000 Sep; 139(5-6):174-9, 248, 247. PubMed ID: 11062945
[TBL] [Abstract][Full Text] [Related]
27. Lomustine and melphalan cannot be replaced by cyclophosphamide and etoposide without reducing efficacy in MOPPEBVCAD chemotherapy for advanced Hodgkin's disease.
Gobbi PG; Broglia C; Bertè R; Petrilli MP; Molica S; Angrilli F; Iannitto E; Ghirardelli ML; Di Renzo N; Cavanna L; Ascari E
Haematologica; 2000 Jul; 85(7):722-8. PubMed ID: 10897124
[TBL] [Abstract][Full Text] [Related]
28. Results of recent salvage chemotherapy regimens for lymphoma and Hodgkin's disease.
Cabanillas F; Velasquez WS; McLaughlin P; Jagannath S; Hagemeister FB; Redman JR; Swan F; Rodriguez MA
Semin Hematol; 1988 Apr; 25(2 Suppl 2):47-50. PubMed ID: 3041599
[TBL] [Abstract][Full Text] [Related]
29. DICE (dexamethasone, ifosfamide, cisplatin, etoposide) infusional chemotherapy for refractory or relapsed non-Hodgkin's lymphoma (NHL).
Coleman M; Leonard J; Shuster MW; Kaufman TP
Eur J Haematol Suppl; 2001 Jul; 64():41-5. PubMed ID: 11486401
[TBL] [Abstract][Full Text] [Related]
30. Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation.
Mandigers CM; Verdonck LF; Meijerink JP; Dekker AW; Schattenberg AV; Raemaekers JM
Bone Marrow Transplant; 2003 Dec; 32(12):1159-63. PubMed ID: 14647270
[TBL] [Abstract][Full Text] [Related]
31. [Treatment results and prognostic significance of selected clinical and laboratory features in children diagnosed with malignant lymphoma].
Kamieńska E
Ann Acad Med Stetin; 1996; 42():105-22. PubMed ID: 9199116
[TBL] [Abstract][Full Text] [Related]
32. [Outcome of 70 patients diagnosed with Hodgkin's disease after first-line and salvage treatment: experience at one center].
Arranz R; Gil-Fernández JJ; Muñoz E; Acevedo A; Sobrino MP; Fernández-Rañada JM
Sangre (Barc); 1998 Jun; 43(3):179-84. PubMed ID: 9741222
[TBL] [Abstract][Full Text] [Related]
33. Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation.
Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E
Biol Blood Marrow Transplant; 2005 Sep; 11(9):688-97. PubMed ID: 16125639
[TBL] [Abstract][Full Text] [Related]
34. Low acute hematological toxicity during chemotherapy predicts reduced disease control in advanced Hodgkin's disease.
Brosteanu O; Hasenclever D; Loeffler M; Diehl V;
Ann Hematol; 2004 Mar; 83(3):176-82. PubMed ID: 15064867
[TBL] [Abstract][Full Text] [Related]
35. Lomustine (chloroethylnitrosourea [CCNU]), ifosfamide, bleomycin, vincristine, and cisplatin (CIBO-P) is an effective regimen for patients with poor prognostic refractory or multiple disease recurrent aggressive non-Hodgkin lymphoma.
Musolino A; Perrone MA; Michiara M; Delnevo D; Franciosi V; Di Blasio B; Ceci G; Camisa R; Ardizzoni A; Cocconi G
Cancer; 2005 May; 103(10):2109-17. PubMed ID: 15803492
[TBL] [Abstract][Full Text] [Related]
36. Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5.
Sieber M; Tesch H; Pfistner B; Rueffer U; Lathan B; Brosteanu O; Paulus U; Koch T; Pfreundschuh M; Loeffler M; Engert A; Josting A; Wolf J; Hasenclever D; Franklin J; Duehmke E; Georgii A; Schalk KP; Kirchner H; Doelken G; Munker R; Koch P; Herrmann R; Greil R; Anselmo AP; Diehl V
J Clin Oncol; 2002 Jan; 20(2):476-84. PubMed ID: 11786577
[TBL] [Abstract][Full Text] [Related]
37. Mitoxantrone, etoposide, cisplatin and dexamethasone (MEPD) as salvage chemotherapy in resistant non-Hodgkin's lymphoma.
Vitolo U; Orsucci L; Bertini M; Cavallero G; Gallamini A; Ghio R; Levis A; Rota-Scalabrini D; Resegotti L
Haematologica; 1991; 76(1):43-6. PubMed ID: 2055560
[TBL] [Abstract][Full Text] [Related]
38. VNCOP-B regimen in the treatment of high-grade non-Hodgkin's lymphoma in the elderly.
Zinzani PL; Bendandi M; Gherlinzoni F; Mazza P; Salvucci M; Aitini E; Miggiano MC; Gozzetti A; Tura S
Haematologica; 1993; 78(6):378-82. PubMed ID: 7513674
[TBL] [Abstract][Full Text] [Related]
39. Cardiopulmonary toxicity of different chemoradiotherapy combined regimens for Hodgkin's disease.
Busia A; Laffranchi A; Viviani S; Bonfante V; Villani F
Anticancer Res; 2010 Oct; 30(10):4381-7. PubMed ID: 21036768
[TBL] [Abstract][Full Text] [Related]
40. High-dose chemotherapy with autologous bone marrow transplantation in 50 advanced resistant Hodgkin's disease patients: an Italian study group report.
Carella AM; Congiu AM; Gaozza E; Mazza P; Ricci P; Visani G; Meloni G; Cimino G; Mangoni L; Coser P
J Clin Oncol; 1988 Sep; 6(9):1411-6. PubMed ID: 2458439
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]